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Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer mortality in the US and the world, with a 5-year survival rate of only 15% for all stages
combined.1,2 There has not been any significant decrease in the overall 5-year mortality
rate for .4 decades despite the investment of billions of dollars into research.3 This
could be attributed to lack of precise process of screening, heterogeneity of diseases,
and, most importantly, the lack of novel therapies coming through.
MicroRNAs (miRNAs) are a novel RNA-interference technology that is currently
being explored as a promising strategy in lung cancer treatment. They are small in
size (~22 nucleotides), and they regulate gene expression at the post-transcription
level through RNA interference. They may be seen as a new tool in the box for cancer
treatment. Members of miRNA-29 family have been known to play an important role
in cancer by regulating cell differentiation, proliferation, apoptosis, invasion, and
migration.4,5 However, clinical application of this relatively novel therapeutic faces
many challenges, including degradation in serum, rapid blood clearance, stimulation of immune response, off-target effects, and poor cellular uptake.6 Recently,
our group developed a novel targeted hybrid nanoparticle delivery system.7–9 This
delivery system demonstrated its ability to protect loaded oligonucleotide against
serum nuclease, reduce rate of blood clearance, efficient cellular uptake, and selective
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Abstract: MicroRNAs (miRNAs) are potentially attractive candidates for cancer therapy.
However, their therapeutic application is limited by lack of availability of an efficient delivery
system to stably deliver these potent molecules intracellularly to cancer cells while avoiding
healthy cells. We developed a novel aptamer-hybrid nanoparticle bioconjugate delivery system
to selectively deliver miRNA-29b to MUC1-expressing cancer cells. Significant downregulation
of oncoproteins DNMT3b and MCL1 was demonstrated by these MUC1 aptamer-functionalized
hybrid nanoparticles in A549 cells. Furthermore, downregulation of these oncoproteins led to
antiproliferative effect and induction of apoptosis in a superior version when compared with
Lipofectamine 2000. This novel aptamer-hybrid nanoparticle bioconjugate delivery system
could potentially serve as a platform for intracellular delivery of miRNAs to cancer cells, hence
improving the therapeutic outcome of lung cancer.
Keywords: aptamer, nanoparticles, microRNA, lung cancer, targeted delivery
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delivery to lung cancer in a mouse model.7–9 This hybrid
nanoparticle delivery system was able to achieve all the
aforementioned abilities because of the uniqueness of its
makeup. Our hybrid nanoparticle technology benefits from
the incorporation of human immunoglobulin G (human IgG)
and poloxamer-188 (polyoxyethylene–polyoxypropylene
block copolymer), to achieve stable and efficient delivery
of nucleic acid-based therapeutics.7 Human IgG is the
main encapsulating component of these hybrid nanoparticles. Human IgG antibody also helps to reduce/eliminate
well-documented immunogenic reaction experienced with
most nanoparticle formulations, by “deceiving” the body
to believe that the nanoparticles are natural components of
the blood.7 Poloxamer-188, a nonionic triblock copolymer,
helps to circumvent the reticuloendothelial system during
systemic circulation, since it has been previously used as a
stealth polymer by preventing macrophage uptake during
circulation.10,11
In the present study, we aim to optimize cellular uptake
of miRNA-29b in lung cancer cells using our novel targeted
hybrid nanoparticle system to selectively deliver miRNA-29b
to lung cancer cells. Furthermore, we demonstrate the
cancer-suppressing and apoptotic ability of encapsulated
miRNA-29b in lung cancer cell lines (A549). We hypothesize
that our novel targeted hybrid nanoparticles will efficiently
deliver loaded miRNA-29b to lung cancer cells while
avoiding normal cells by conjugation of mucin 1 (MUC1)
aptamer to the nanoparticles. Furthermore, we hypothesize
that selectively delivered miRNA-29b will downregulate
oncoproteins myeloid cell leukemia sequence 1 (MCL1)
and DNA methyltransferase 3B (DNMT3B) in lung cancer,
hence inhibiting cancer cell growth.
miRNA-29b is the most abundantly expressed of all
miRNA-29 families in normal cells.12 Previous studies have
demonstrated that miRNA-29b plays an important role in
cancer by regulating cell proliferation, differentiation, and
apoptosis.5,6,13,14 It is usually silenced or downregulated in
lung cancer and other types of cancer.6,15 In contrast, forced
expression in acute myeloid leukemia and lung cancer
resulted in significant reduction of DNMT3B at both protein and mRNA levels by direct interaction.15 Downregulation of DNMT3B led to inhibition of cell proliferation and
apoptosis of lung cancer cells.15,16 Furthermore, MCL1,
a potent antiapoptotic protein of the BCL-2 family, has
been shown to be downregulated by miRNA-29b in cancer
cells.15 miRNA-29b is therefore a very attractive candidate
for miRNA-based therapeutics due to its potent tumor suppressant capabilities.
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To actively and selectively deliver the encapsulated
miRNA-29b to lung cancer cells, these nanoparticles were
functionalized with MUC1 aptamer.
MUC1 is a transmembrane protein that is aberrantly
overexpressed in NSCLCs.17 MUC1 has been shown to be
overexpressed in .80% of lung adenocarcinoma.17 It has also
been shown that targeting MUC1 function inhibits mutant
K-ras signaling in NSCLC cells.17 We aim to take advantage
of this overexpression in NSCLC to achieve an optimized
targeting of miRNA-29b to NSCLC by conjugating MUC1
aptamer to the surface of our hybrid nanoparticles.
Previous studies have shown that MUC1 aptamerfunctionalized nanoparticles improved the efficacy of drug
delivery to breast cancer cells.18

Experimental section
Materials
Human IgG was purchased from Equitech-Bio Inc.
(Kerrville, TX, USA). Poloxamer-188, RNase-free water,
4,6-diamidino-2-phenylindole (DAPI), and fetal bovine
serum (FBS) were obtained from Thermo Fisher Scientific
(Waltham, MA, USA). Aptamer against MUC1 (5′-GCA
GTT GAT CCT TTG GAT ACC CTG G-3′) was designed
and purchased from GE Healthcare Bio-Sciences Corp.
(Piscataway, NJ, USA). A C12 spacer was attached to the
aptamer at the 3′-end to form the following sequence: 5′-GCA
GTT GAT CCT TTG GAT ACC CTG G-C12H25-3′. One
aptamer was modified with 3′-NH2 and 5′-FITC, whereas the
other was only modified with 3′-NH2. The aptamers contained
a 12-carbon spacer. siGLO-Green (6-FAM-labeled) was
obtained from GE Healthcare Bio-Sciences Corp. HCl was
obtained from Thermo Fisher Scientific. MiRIDIAN mimic
with miR-29b and miRIDIAN mimic NC were obtained
from GE Healthcare Bio-Sciences Corp. Pierce RIPA lysis
buffer was purchased from Thermo Fisher Scientific. Rabbit
antihuman DNMT3B and rabbit antihuman MCL1 antibody were obtained from Thermo Fisher Scientific. Mouse
antihuman β-tubulin antibody was purchased from SigmaAldrich (St Louis, MO, USA).

Cell culture
Adenocarcinoma cell line A549 and normal lung fibroblast cell line MRC-5 were obtained from American Type
Culture Collection (Rockville, MD, USA). A549 cell was
originally derived from a 58-year-old male Caucasian,
while MRC-5 was originally derived from a 14-week gestation male Caucasian. A549 cells were maintained in F12 K
medium supplemented with 10% FBS and 1% antibiotics.
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MRC-5 was maintained in Eagle’s Minimum Essential
Medium supplemented with 10% FBS. Both cells were kept
in a humidified air atmosphere with 5% carbon dioxide.
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Preparation of nanoparticles
Human IgG was diluted in 0.01N HCl to make up IgG
concentration of 1 mg/mL (ie, 10 mg) in 10 mL of 0.01 N
HCl. A total of 0.73 mg of miRNA-29b was then added.
The mixture was stirred on a magnetic stirrer until all the
components were fully dissolved. The mixture was titrated
with 0.01 N NaOH up to a pH value close to 7. Nanoparticles
were spontaneously formed at the pH value very close to 7.
The nanoparticles were allowed to mix on the magnetic stirrer
for ~10 minutes. The colloidal suspension was centrifuged
using a microcentrifuge (Eppendorf centrifuge 5418) at
2,000 rpm for 5 minutes. The supernatant was either decanted
or kept for the measurement of unencapsulated miRNA-29b
to be used to calculate encapsulation efficiency and loading capacity. Nanoparticles were then rinsed three times
with double distilled deionized water. Nanoparticles were
subsequently suspended in 0.2% v/v poloxamer-188, with
gentle shaking for 10 minutes in order to coat nanoparticles
with poloxamer-188. Nanoparticles were centrifuged and the
supernatant decanted before being rinsed thrice with double
distilled deionized water. Particles were then loaded into a
freeze dryer (Labconco Freeze Zone 4.6), and lyophilization
was performed for 48 hours.

Conjugation of aptamer to prepared
nanoparticles

A total of 50 µL of poloxamer-free nanoparticle suspension
(10 µg/mL in DNase, RNase-free water) was mixed with
100 µL of 40 mM EDC and 100 µL of 10 mM NHS for
15 minutes at room temperature with gentle stirring. This
helps to activate the carboxyl groups on nanoparticles for
aptamer conjugation. A total of 50 µL of 1 µg/mL aptamer in
DNase, RNAse-free water was then added to the nanoparticles
and mixed gently for 2 hours at room temperature. Nanoparticles were subsequently centrifuged at 4,000 rpm and 10°C for
5 minutes using 30 kDa cutoff centrifugal ultrafilters (EMD
Millipore, Billerica, MA, USA) to exclude unreacted EDC
and NHS. Aptamer-functionalized nanoparticles were then
suspended in 0.2% v/v poloxamer-188, with gentle shaking
for 10 minutes in order to coat them with poloxamer-188.

Characterization of nanoparticles
Particle size and surface charge (zeta potential) of the nanoparticles were measured using photon correlation spectroscopy
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(ZetaSizer Nano ZS; Malvern Instruments, Malvern, UK).
Nanoparticles were dispersed in deionized water followed
by sonication for ~5 minutes. A scattering angle (θ ) of
173° was used to measure intensity autocorrelation. The
Z-average and polydispersity index were recorded in triplicate. For zeta potential, samples were taken in a universal dip
cell (Malvern Instruments) and the zeta potential recorded
in triplicate.
We evaluated the shape of nanoparticles using scanning
electron microscopy. Suspensions of nanoparticles were
dropped on an aluminum stub and allowed to dry at room
temperature. Samples were then coated with a thin layer of
palladium. Coated samples were imaged using a Zeiss Supra
50 V system (Carl Zeiss Meditec AG, Jena, Germany).

Fourier transform-infrared spectroscopy
A single-reflection-attenuated total reflectance with a diamond internal reflection crystal installed in an iS10 FT-IR
spectrometer (Thermo Fisher Scientific) was used to obtain
spectra from different samples of nanoparticles. Lyophilized
powders were placed on the surface of the attenuated total
reflectance crystal after background spectra had been collected. Spectra were collected after 64 scans at 4 cm-1 resolution. Data were analyzed using OMNIC software.

miRNA release study
Release of miRNA from MUC1 aptamer-functionalized
hybrid nanoparticles was measured at pH values 5, 6.6, and
7.4. Nanoparticles (3 mg) were dispersed in 0.5 mL of a
buffered solution in a tubular cellulose dialysis membrane
secured tightly at both ends. This was then incubated at 37°C
in 5 mL buffered solution reservoirs while the reservoir was
gently agitated. The amount of miRNA released at different time points was analyzed and quantified for percentage
cumulative release using ion-pair HPLC.

Ion-pair HPLC
miRNA was quantitatively determined using a Waters
2695 separation module combined with a Waters 2998
photodiode array detector Alliance HPLC system (Waters,
Milford, MA, USA). Using a Clarity 3 μm Oligo-RP column
(Phenomenex, Torrance, CA, USA) with a column dimension
of 50×2.0 mm, 1 μL of miRNA sample was injected into
the HPLC using 20 mM triethylamine–acetic acid (pH 7)
and 5%–12% acetonitrile, gradient elusion as mobile phase.
A flow rate of 0.2 mL/min was used for analysis. UV detection was performed at 269 nm, and Empower Pro software
was used to record chromatograms.
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Fluorescence microscopy
A549 cells were seeded at a density of 2×104 in eight-well coated
glass slides (Discovery Labware, Tewksbury, MA, USA) followed by incubation for 48 hours. Cells were washed with PBS
and incubated with either FITC-MUC1 aptamer-functionalized
miRNA-29b-loaded hybrid nanoparticles or MUC1 aptamerfunctionalized siGLO-FAM-loaded hybrid nanoparticles dispersed in the Opti-Mem medium at a concentration of 100 μg/mL
for 2 hours or 4 hours. Cells were then washed twice with
PBS, fixed using 2% paraformaldehyde, and incubated at room
temperature for 20 minutes. Cells washed with PBS were then
blocked with 5% BSA for 30 minutes at room temperature. Cells
were stained with either Lysotracker-Red or AlexaFluoro-555
-labeled wheat germ agglutinin (WGA-AF-555) before being
stained with DAPI to visualize nucleus. Leica DMI 6000B fluorescence microscope (Leica Microsystems, Wetzlar, Germany)
was then used to observe cells after being mounted.

Reverse transcriptase polymerase chain
reaction
Qiagen RNAeasy kit (Qiagen, NV, Venlo, the Netherlands)
was used to isolate total RNA and Verzo cDNA kit (Thermo
Fisher Scientific) was used for reverse transcription. Polymerase chain reaction (PCR) was carried out in 25 μL reaction mixtures. These reaction mixtures contained 1.0 μL of
cDNA, 1× Qiagen buffer, 0.2 mM of dNTP mixture, 0.2 μM
of each primer, and 1.5 U of HotStar Taq (Qiagen, Valencia,
CA, USA). One cycle reaction at 95°C for 15 minutes was
followed by 35 amplification cycles (94°C for 1 minute,
66°C for 1 minute, and 72°C for 1 minute) for MUC1. For
β-actin PCR, the same conditions except for the annealing
temperature (59°C) were used. Primer sequences of MUC1
are forward 5′-TCTCAAGCAGCCAGCGCCTGCCTG-3′,
reverse 5′-TCCCCAGGTGGCAGCTGAACC-3′ and
β-actin, forward 5′-CCAAGGCCAACCGCGAGAAGAT-3′,
and reverse 5′-TTGCTCGAAGTCCAGGGCGA-3′.

Flow cytometry
Approximately 1 million cells per well (A549 and MRC-5)
were seeded in a six-well plate and incubated for 48 hours.
Cells were then treated with 100 μg/mL of siGLO-FAMloaded equivalent nanoparticles resuspended in Opti-MEM
medium and incubated for 4 hours. Corresponding cells were
pretreated with five times excess of free MUC1 aptamer,
60 minutes prior to being treated with the MUC1 aptamerfunctionalized siGLO-FAM-loaded hybrid nanoparticles.
Cells were washed with PBS. The cells were then detached
by trypsinization and centrifuged at 1,000 rpm for 5 minutes.
The pellet was washed and resuspended in PBS. A 0.75 μm
3536
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cell strainer was used to filter the cells before being analyzed
by flow cytometry (BDFACS caliber) to prevent cell aggregates from blocking the tube lines of the instrument. A total
of 10,000 cells were measured in each sample.

Cell death detection ELISA
Cell death detection ELISA was carried out according to
manufacturer’s instructions (Hoffman-La Roche Ltd., Basel,
Switzerland). Briefly, A549 cells were seeded at a density
of 2×104/well for 24 hours. Next day they were treated with
MUC1 aptamer-functionalized miR-29b-loaded hybrid
nanoparticles, MUC1 aptamer-functionalized negative control miRNA-loaded hybrid nanoparticles, and miR-29b in
Lipofectamine 2000 Transfection Agent (Ambion, Austin,
TX, USA) in Opti-MEM medium. Cells were washed in PBS
and lysed in 200 µL/well of incubation buffer for 30 minutes
at room temperature. The lysates were centrifuged at
4,000× g for 10 minutes. Supernatant was used right away in
the experiment. Plastic wells of the ELISA kit were incubated
with coating solution (containing antihistone antibodies)
overnight at 4°C. Next day it was substituted by incubation
buffer for 30 minutes and washed three times with washing
solution. A total of 100 µL of homogenate was placed into
the wells and incubated for 90 minutes at room temperature
with mild shaking. It was washed three times and incubated
with conjugate solution containing anti-DNA peroxidase
antibodies for 90 minutes. Wells were washed three times
and exposed to ABTS substrate for 30 minutes until the color
developed. Absorption values were read using a BioTek
Epoch Microplate Spectrophotometer (BioTek Instruments
Inc., Winooski, VT, USA) with Gen5 1.10 software.

Western blot analysis
One million A549 cells per well were seeded in culture dish
and incubated for 48 hours. Cells were treated with MUC1
aptamer-functionalized miR-29b-loaded hybrid nanoparticles
(at an equivalent concentration of 100 nM of miRNA-29b),
MUC1 aptamer-functionalized negative control miRNAloaded hybrid nanoparticles as well as miR-29b in Lipofectamine 2000 reagent in Opti-MEM medium for 3 days.
Cells were lysed in Pierce® RIPA buffer (Thermo Fisher
Scientific) with addition of Pierce™ Protease Inhibitor Mini
Tablets (Thermo Fisher Scientific) for 30 minutes on ice and
centrifuged for 10 minutes at 10,000× g at +4°C. The protein
concentration was determined with the Coomassie Plus™
(Bradford) Assay Kit (Thermo Fisher Scientific). A total of
120 µg of total proteins was separated on NuPAGE 4%–12%
Bis–Tris gels (Thermo Fisher Scientific) with NuPAGE
MES SDS running buffer (Thermo Fisher Scientific) and
International Journal of Nanomedicine 2016:11
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subsequently transferred onto a nitrocellulose membrane
with a pore size of 0.22 µm (Thermo Fisher Scientific). The
membrane with proteins was blocked according to manufacturer’s instructions (Thermo Fisher Scientific) for 1 hour at
room temperature and probed with primary antibodies overnight at 4°C DNMT3B (1:1,000, Thermo Fisher Scientific)
and MCL1 (1:500; Thermo Fisher Scientific). β-Tubulin was
used as a housekeeping gene (1:2,000, Sigma-Aldrich). Next
day the membranes were washed three times for 5 minutes
in wash buffer according to manufacturer’s instructions
(Thermo Fisher Scientific) and incubated with secondary goat
antimouse (Molecular Probes, Eugene, OR) or goat antirabbit
(1:1,000, Thermo Fisher Scientific) secondary antibodies, conjugated with horseradish peroxidase at a dilution of 1:1,000.
Immune complexes were detected with chemiluminescent
substrate, Pierce ECL Western Blotting substrate (Thermo
Fisher Scientific), in a dark room on tabletop processor SRX101A (Konica Minolta, Tokyo, Japan).

Cell viability
MTT assay was used to determine the effect of MUC1
aptamer-functionalized miRNA-29b-loaded hybrid nanoparticles on the proliferation of A549 cells. Cells (1×104) per
well were seeded in 96-well plates and incubated at 37°C in a
humidified atmosphere with 5% carbon dioxide for 24 hours.
The cells were then treated with different concentrations of
miRNA-29b-loaded hybrid nanoparticles in Opti-MEM for
7 hours before being replaced with F12 K medium supplemented with 10% FBS and 1% antibiotics. This was then
incubated for 72 hours. miRNA-29b transfected with NeoFX
transfection agent was used as control in this experiment.
Approximately 10 μL of 12 mmol/L MTT reagent was
then added to each well. This was then incubated at 37°C
for 4 hours. The medium was aspirated and 50 μL of sterile
dimethyl sulfoxide was added to each well and mixed thoroughly with pipette. The cells were then incubated at 37°C
for 10 minutes. The plate was read at 540 nm and 650 nm.

Statistical analysis

Results are presented as mean ± SD, unless otherwise indicated. Statistically significant difference between two groups
was determined by two-tailed Student’s t-test. A P-value of
0.05 was taken as statistically significant.

Results
Nanoparticle characterization
Particle size and zeta potential analysis by photon correlation
spectroscopy, shown in Table 1, demonstrated that nonfunctionalized hybrid nanoparticles were ~240 nm in size,
International Journal of Nanomedicine 2016:11
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Table 1 Particle size and zeta potential of nonfunctionalized and
aptamer-functionalized hybrid nanoparticles (mean ± SD, n=3)
Nanoparticle
sample

Mean
diameter
(nm)

Polydispersity
index

Zeta
potential
(mV)

Nonfunctionalized
nanoparticles
Aptamer-functionalized
nanoparticles

236.2±35.1

0.242±0.007

-2.1±1.7

595.9±43.1

0.554±0.386

+4.1±1.0

while MUC1 aptamer-functionalized hybrid nanoparticles
were ~595 nm in size. Nonfunctionalized hybrid nanoparticles were negatively charged with a zeta potential of -2.1,
while the conjugation of MUC1 aptamer increased the zeta
potential of these nanoparticles to +4.1.
The schematic of the MUC1 aptamer-functionalized
hybrid nanoparticle is shown in Figure 1A. Scanning electron
micrograph in Figure 1B reveals that the hybrid nanoparticles
were spherical in shape with smooth surface.
miRNA encapsulation efficiency (EE) and loading capacity (LC) were measured using ion-pair HPLC analysis of the
filtrates obtained by centrifuging the nanoparticles formed to
determine the amount of unencapsulated miRNA-29b. EE
and LC were calculated using the following equation:
%EE =

A−B
A−B
× 100, and %LC =
× 100 (1)
A
C

where A = total amount of miRNA, B = free miRNA, and
C = weight of hybrid nanoparticles in grams.
EE was calculated to be 98.8%±0.4%, whereas LC was
calculated to be 8.6%±0.1%.
Conjugation of MUC1 aptamer to the surface of the nanoparticles was verified using fluorescence microscopy. Figure 1C
demonstrates the successful conjugation of FITC-MUC1
aptamer to the nanoparticles by the presence of fluorescent
green color in the micrograph. In contrast, nonfunctionalized
hybrid nanoparticles in Figure 1D showed the absence of
fluorescent green color, confirming the lack of FITC-MUC1
aptamer in the nanoparticles. We also used Fourier transforminfrared (FT-IR) to confirm the successful conjugation of
MUC1 aptamer to the nanoparticles. Figure 1E shows the FT-IR
spectra generated from functionalized and nonfunctionalized
hybrid nanoparticles. A distinctive and conspicuous difference
between these sets of spectra bears testament to the successful
conjugation of MUC1 aptamer to the hybrid nanoparticles.

In vitro release study
The release of miRNA-29b from MUC1 aptamer-functionalized
hybrid nanoparticles was compared at pH values 5, 6.6,
submit your manuscript | www.dovepress.com
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Figure 1 Hybrid nanoparticle characterization.
Notes: (A) Schematic of the aptamer-functionalized hybrid nanoparticle. (B) Scanning electron micrograph of miRNA-loaded hybrid nanoparticles (scale bar: 500 nm).
(C) Fluorescence micrograph of FITC-MUC1 aptamer-functionalized hybrid nanoparticles (scale bar: 25 µm). (D) Fluorescent micrograph of nonfunctionalized hybrid
nanoparticles (scale bar: 25 µm). (E) FT-IR spectra of different nanoparticles to confirm the conjugation of aptamer to the nanoparticles.
Abbreviations: FT-IR, Fourier transform-infrared; IgG, immunoglobulin G; miRNA, microRNA; MUC1, mucin 1.

and 7.4. Figure 2 demonstrates a limitation in the release of
miRNA-29b at pH values 6.6 and 7.4 when compared with
the release profile at pH 5.

Expression of MUC1 protein in NSCLC
cells
Reverse transcriptase PCR was used to confirm the expression of MUC1 in two NSCLC cells, A549 and H460, to
ensure that these cells actually express MUC1. Figure 3A
demonstrates the relatively higher expression of MUC1 in
both cancer cells when compared with normal lung fibroblast
cell line MRC-5.
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Cellular uptake of MUC1 aptamerfunctionalized hybrid nanoparticles
Internalization of nanoparticles was evaluated using both
flow cytometry and fluorescence microscopy. Flow cyto
metry was used to compare nanoparticle uptake by A549
and MRC-5. siGLO-FAM (green) was used as a model
small double-stranded RNA labeled with FAM (a green
dye). MUC1 aptamer conjugated to siGLO-loaded hybrid
nanoparticles used in this experiment was bereft of FITC
so as to avoid double fluorescence. As shown in Figure 3B,
internalization of MUC1 aptamer-functionalized siGLOFAM-loaded nanoparticles in A549 cells was significantly
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Figure 2 In vitro release.
Notes: Release profiles show that only a limited amount of microRNA-29b was
released at pH values 6.6 and 7.4. However, an optimal release was observed at pH 5.

higher (P#0.001) in noninhibited cells when compared with
cells pretreated with MUC1 aptamer. Furthermore, uptake
of nanoparticles by MRC-5 was much lower than the uptake
by A549 cells.

Fluorescence microscopy was used to study the interaction
of FITC-MUC1 aptamer-functionalized hybrid nanoparticles
with the cell membrane of A549 cells. Figure 4A demonstrates the presence of FITC-MUC1 aptamer-functionalized
hybrid nanoparticles (green color) on the cell membrane and
inside the cytosol of A549 cells after 2 hours of incubation.
Cell membrane of cells was stained with WGA-Alexa Fluor
555 (red color) to enable the identification of the boundaries of cells. Colocalization of both green and red colors on
the membrane of the cells suggests a possible interaction
between the FITC-MUC1 aptamer-functionalized hybrid
nanoparticles and the membrane of the cells possibly due to
the presence of MUC1 on the membrane.
Intracellular trafficking of internalized nanoparticles
was also monitored using fluorescence microscopy. Late
endosomes/lysosomes were labeled with LysoTracker-Red
to enable the monitoring of the fate of internalized nanoparticles. Figure 4B demonstrates maximum level of colocalization of siGLO-FAM and LysoTracker-Red after 2 hours of
incubation. However, after 4 hours, the siGLO-FAM was
observed to be leaving the late endosomes and moving into
the cytoplasm as indicated by the numerous green colored
dots surrounding the nucleus.
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Figure 3 Impact of MUC1 expression levels on MUC1 aptamer-functionalized hybrid nanoparticle internalization.
Notes: (A) Reverse transcriptase PCR showing levels of expression of MUC1 in selected cells (n=3). (B) Comparison of nanoparticle internalization by A549 and MRC-5
using flow cytometry. **P#0.001, n=3.
Abbreviations: GAPDH, glyceraldehyde 3-phosphate dehydrogenase; MUC1, mucin 1.
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Figure 4 Fluorescence microscopy of nanoparticle–cell membrane interaction.
Notes: (A) Micrographs showing the interaction between FITC-MUC1 aptamer-functionalized nanoparticles and cell membrane after 2-hour incubation. (B) Micrographs
showing intracellular trafficking of internalized siGLO-FAM-loaded nanoparticles.
Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; MUC1, mucin 1.

MUC1 aptamer-functionalized miRNA-29bloaded hybrid nanoparticles downregulate
DNMT3B and MCL1 proteins and induce
apoptosis in A549 cells
Figure 5A demonstrates the knockdown efficiency of MUC1
aptamer-functionalized miRNA-29b-loaded nanoparticles
against DNMT3B. These nanoparticles produced superior
downregulation of DNMT3B when compared with Lipofectamine 2000 transfected miRNA-29b and the negative
control miRNA-loaded nanoparticles. Figure 5B further
demonstrates the superior transfection efficiency of MUC1
aptamer-functionalized miRNA-29b-loaded nanoparticles
in comparison to lipofectamine by effectively downregulating MCL1. In contrast, both lipofectamine and MUC1
aptamer-functionalized negative control miRNA-loaded
hybrid nanoparticles did not achieve the same level of
downregulation.
Superior induction of apoptosis was observed in A549
cells treated with MUC1 aptamer-functionalized miRNA29b-loaded hybrid nanoparticles when compared with
nontreated cells, MUC1 aptamer-functionalized negative
control miRNA-loaded hybrid nanoparticles-treated cells and
lipofectamine-transfected miRNA-29b (Figure 5C).
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Antiproliferative effect of MUC1 aptamer-functionalized
miRNA-29b-loaded nanoparticles was evaluated using
MTT assay and compared with that of NeoFX-transfected
miRNA-29b and negative control miRNA-loaded nanoparticles in A549 cells. As demonstrated in Figure 5D, MUC1
aptamer-functionalized miRNA-29b-loaded nanoparticles
were significantly more cytotoxic to A549 cells than NeoFXtransfected miRNA-29b and negative control miRNA-loaded
miRNA nanoparticles.

Discussion
Translational application of miRNA-based therapeutics is
limited by a lack of smart nanoparticle delivery system to
selectively deliver these important molecules intracellularly
to cancer cells.
Recently, our group developed a novel hybrid nanoparticles delivery system for safe and effective delivery of nucleic
acid-based therapeutics to lung cancer.7–9 These nanoparticles
were able to protect loaded nucleic acid against serum nuclease
both in vitro and in vivo.7,9 Furthermore, these hybrid nanoparticles were able to successfully deliver siRNA against mutant
K-ras to the cytosol of A549 lung cancer cell lines without
eliciting immunogenic/inflammatory response in murine
macrophages, RAW 264.7.7,8 A significant downregulation of
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Figure 5 Effect of miRNA-29b on essential oncoproteins in A549 cells.
Notes: (A) Downregulation of DNMT3B by miRNA-29b nanoparticles. (B) Downregulation of MCL1 by miRNA-29b nanoparticles. miR-29b-nano represents MUC1 aptamerfunctionalized miRNA-29b-loaded hybrid nanoparticles: NC-nano represents MUC1 aptamer-functionalized negative control miRNA-loaded hybrid nanoparticles; miR-29blipo represents lipofectamine 200-transfected miRNA-29b. (C) Cell death detection ELISA showing the induction of apoptosis in A549 cells (n=3). (D) Antiproliferative effect
of miRNA-29b nanoparticles in A549 cells (n=5).
Abbreviations: DAPI, 4,6-diamidino-2-phenylindole; miRNA, microRNA; MUC1, mucin 1.

both protein and mRNA of K-ras was achieved.7 In the present
study, we were able to show that these nanoparticles could be
functionalized with MUC1 aptamer to enable selective delivery of miRNAs to NSCLC cells. miRNA-29b was selected
as a model miRNA since it has been previously reported
that miRNA-29b, a tumor suppressor miRNA, is aberrantly
expressed in NSCLC and its perturbation is related to tumor
development and progression.4–6,19 Hence, miRNA-29b has
been identified as an attractive candidate for miRNA-based
therapeutics in NSCLC.
Hybrid nanoparticles comprising human IgG and
poloxamer-188 were prepared using our previously reported
isoelectric point (pI)-based nanoprecipitation technology.7,8,20
This technology is based on the fact that proteins (human
IgG) have minimum solubility but maximum precipitation
at their pI. Nanoparticles produced using this technology
are characteristically spherical in morphology as seen in
Figure 1B. The particles were negatively charged possibly
because of the presence of residual miRNA on the surface

International Journal of Nanomedicine 2016:11

of the nanoparticles. However, the charge on the particles
became positive following the conjugation of aptamer to
the surface of the nanoparticles. The positive charge could
be attributed to the presence of an amino group NH2 in the
aptamer to facilitate the conjugation reaction. The loss of
the lone pair of electrons on the amino group resulted in
the positive charges. Both fluorescence microscopy and
FT-IR analysis were performed to confirm the successful
conjugation of MUC1 aptamer to the preformed hybrid
nanoparticles. As shown in Figure 1C, FITC-labeled MUC1
aptamer present on the surface of the hybrid nanoparticles
led to the presence of green color in the MUC1 aptamerfunctionalized hybrid nanoparticles. In contrast, nonfunctionalized hybrid nanoparticles did not show any green color
in Figure 1D. This method of confirmation of successful
aptamer conjugation to nanoparticles has been previously
reported by Farokhzad et al.21 FT-IR data in Figure 1E
demonstrate a distinctive difference between the spectra of
MUC1 aptamer-functionalized hybrid nanoparticles and the
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nonfunctionalized hybrid nanoparticles. Nonfunctionalized
hybrid nanoparticles had a peak at 3,274 cm-1, which can
be attributed to the group stretching vibration of both NH2
and OH in the human IgG.22,23 Following the conjugation of
MUC1 aptamer to the hybrid nanoparticles, this peak became
sharper and more intense due to the presence of additional
NH2 and OH stretching vibration attributable to the conjugation of NH2 aptamer to the hybrid nanoparticles. Both MUC1
aptamer-functionalized and nonfunctionalized nanoparticles
show a peak at ~1,541 cm-1, which could be attributed to the
presence of amide II carbonyl stretch from human IgG in
both nanoparticles.24 Furthermore, the peak at ~1,660 cm-1
found in the spectra for MUC1 aptamer-functionalized hybrid
nanoparticles but absent in the corresponding nonfunctionalized hybrid nanoparticles is attributed to conjugated amide
stretching due to the conjugation of the amino group from the
aptamer to the carboxyl groups present in human IgG.
Figure 2 demonstrates a limitation in the release of
miRNA from MUC1 aptamer-functionalized hybrid nanoparticles at pH values 6.6 and 7.4 when compared with the release
profile at pH 5. This demonstrates the pH-sensitive nature of
these nanoparticle delivery systems. At pH values of 6.6 and
7.4, very limited amount of the loaded miRNA (,20%) was
released throughout the study period. The limited release of
siRNA at pH values 6.6 and 7.4 could be attributed to the
reduced/limited solubility of human IgG at these pH values.
Proteins are known to have limited solubility at pH values
close to their pI.22 Since the pI of human IgG is 7, its solubility
at neutral pH values is quite limited. This makes it difficult
for the encapsulated miRNA to be released at this pH value,
hence possibly limiting its release extracellularly in blood and
tumor microenvironment. However, at acidic pH value of 5,
an optimal miRNA release of ~100% was obtained due to the
solubility of human IgG at this pH. An optimum release of the
loaded miRNA is very desirable at pH 5, as pH 5 represents
the acidic condition of endosome/lysosome.25,26
Uptake of MUC1 aptamer-functionalized nanoparticles,
as demonstrated in Figure 3B, is significantly higher in
A549 cells in comparison to MRC-5 cells. The differential
internalization of nanoparticles between these cell lines could
be attributed to the differential expression of MUC1 on the
surface of these cells. While A549 is an adenocarcinoma cell
line that is known to aberrantly overexpress MUC1,17 MRC-5
is a normal lung fibroblast cell line with limited expression
of MUC1 as shown in Figure 3A. To further confirm the
involvement of MUC1 in the internalization of these nanoparticles, cells were pretreated with free MUC1 aptamer prior
to their treatment with the MUC1 aptamer-functionalized
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hybrid nanoparticles to further elucidate the role of MUC1
in uptake of nanoparticles. In Figure 3B, the significantly
lower uptake of nanoparticles by A549 cells following pretreatment with free MUC1 aptamer could be attributed to
competitive binding of this free MUC1 aptamer to MUC1
on the membrane of the cells, limiting the uptake of MUC1
aptamer-functionalized hybrid nanoparticles. Figure 4A
further demonstrates the interaction between the cell membrane of A549 cells and FITC-MUC1 aptamer conjugated
to the hybrid nanoparticles. Presence of green color on the
membrane of the A549 cells suggests the binding of these
nanoparticles to the membrane prior to internalization.
One of the challenges facing the translational application
of nanomedicine is the lack of effective endosomal escape
following internalization by host cells. Stable nucleic acid
lipid particles, which to date are the most advanced delivery
system for nucleic acid, have demonstrated some limitation
in recent studies. It was revealed that ~70% of the internalized nucleic acid undergoes exocytosis (endocytic recycling)
through egress of the lipid nanoparticles from late endosomes
and lysosomes.27 It is therefore important to design nanoparticle delivery system with the ability to escape the recycling
pathways. To demonstrate the ability of our hybrid nanoparticles to escape endocytic recycling, we monitored intracellular
trafficking of internalized nanoparticles using fluorescence
microscopy. In Figure 4B, colocalization of nanoparticles
(green) and endosome (red) indicates the presence of nanoparticles in the late endosome after 2 hours of incubation.7
However, release of siGLO-FAM (green) can be seen after
4 hours of incubation, indicating the escape of encapsulated
siGLO-FAM from late endosomes into the cytosol of the
cells. This was possible due to the buffering capacity of the
hybrid nanoparticles in the endosome. The solubility of IgG
and poloxamer-188 at acidic pH 5, as demonstrated by the
in vitro release data in Figure 2, makes it possible for the
dissolved IgG in the endosome to activate the proton pump
that raises osmotic pressure in the endosome subsequently
leading to the swelling and subsequent escape of siGLOFAM from the endosomes into the cytoplasm.27,28
To evaluate the ability of internalized miRNA-29b to
downregulate target oncoproteins DNMT3B and MCL1,
expression of these proteins was monitored using Western blot.
As demonstrated in Figure 5A and B, both target oncoproteins
were downregulated in A549 cells following treatment with
MUC1 aptamer-functionalized miRNA-29b-loaded hybrid
nanoparticles in a superior version when compared with
lipofectamine-transfected miRNA-29b. DNMT3B has been
identified as a member of the DNA methyltransferase family

International Journal of Nanomedicine 2016:11

International Journal of Nanomedicine downloaded from https://www.dovepress.com/ by 147.140.233.17 on 09-Sep-2016
For personal use only.

Dovepress

accounting for inactivation of tumor suppressor genes in
many cancer cells.29 miRNA-29b has been reported to exert
its tumor-suppressive role by directly targeting DNMT3b in
cancer cells.5,6,29 Furthermore, miRNA-29b has been reported
to be downregulated in malignant cells, whereas MCL1 was
upregulated.5,6,30 MCL1 is a potent antiapoptic protein of the
BCL-2 family. Downregulation of both DNMT3B and MCL1
by miRNA-29b has been shown to inhibit cancer cell growth
and promote apoptosis.29,30 However, the challenge facing the
clinical application of miRNA-29b to cancer therapy is the
availability of an efficient and safe delivery system to enhance
intracellular delivery of this potent molecule to cancer cells.
Figure 5A and B demonstrates the superior efficiency of MUC1
aptamer-functionalized miRNA-29b-loaded hybrid nanoparticles in downregulating oncoproteins DNMT3b and MCL1
in NSCLC cells over lipofectamine-delivered miRNA-29b.
The ability of this treatment modality to induce apoptosis in
A549 cells due to downregulation of DNMT3B and MCL1
was also demonstrated in Figure 5C. MUC1 aptamer miRNA29b-loaded hybrid nanoparticles also demonstrated superior
antiproliferative effect in A549 cells in comparison to NeoFXdelivered miRNA-29b. NeoFX is another commonly used,
commercially available nucleic acid transfection agent.

Conclusion
MUC1 aptamer-functionalized hybrid nanoparticle delivery
system was successfully fabricated. Our results demonstrated
that this delivery system can efficiently deliver miRNAs
effectively to cancer cells in a superior version compared
with commercially available transfection agents. We also
demonstrated that direct downregulation of DNMT3b and
MCL1 led to antiproliferative effect in A549 cells. This novel
aptamer-hybrid nanoparticle bioconjugate delivery system
could potentially serve as a platform for intracellular delivery
of miRNAs to cancer cells, hence improving the therapeutic
outcome of lung cancer.
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